Glioma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Recent studies have shown that PCBP2 is overexpressed and plays an important role in human cancers, including glioma.
|
26722446 |
2015 |
Glioma
|
0.040 |
Biomarker
|
disease |
BEFREE |
PCBP2 may facilitate miR-151-5p and miR-16 promotion of glioma cell migration and invasion through mitigating the function of ARHGDIA.
|
26761212 |
2016 |
Glioma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In summary, our findings implicate that SIRT6 inhibits PCBP2 expression through deacetylating H3K9ac and SIRT6 acts as a tumor suppressor in human glioma.
|
24607900 |
2014 |
Glioma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Expression of PCBP2 in glioma tissues and cells were higher than that in paracancerous tissues and normal cells (both p < .01).
|
31693182 |
2020 |
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Statistical results also indicated that PCBP2 expression level was significantly positively correlated with ESCC clinicopathological parameters such as tumor grade and tumor size.
|
27461833 |
2016 |
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
In summary, our findings implicate that SIRT6 inhibits PCBP2 expression through deacetylating H3K9ac and SIRT6 acts as a tumor suppressor in human glioma.
|
24607900 |
2014 |
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Overexpression of β2-AR and PCBP2 was associated with advanced tumor stage and significantly worsened prognosis in patients with PDAC.
|
26803058 |
2016 |
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
In vivo assay, PCBP2 was also found to inhibit the tumor growth of glioma.
|
31693182 |
2020 |
Hepatitis C
|
0.030 |
Biomarker
|
disease |
BEFREE |
It is interesting to note that most initiation factors known to bind or interact with the hepatitis C virus internal ribosome entry site [poly(rC)-binding protein 2, polypyrimidine tract binding protein, eukaryotic initiation factor 3, eukaryotic initiation factor 2gamma, eukaryotic initiation factor 2beta, La protein, and heterogenous nuclear ribonucleoprotein L] were induced during the S and G 2 /M phases.
|
15685555 |
2005 |
Hepatitis C
|
0.030 |
Biomarker
|
disease |
BEFREE |
We used a biotinylated RNA pulldown approach to isolate host factors binding to the HCV 5' terminal 47 nucleotides and, in addition to Ago2 and PCBP2, identified several novel proteins, including IGF2BP1, hnRNP L, DHX9, ADAR1, and NF90 (ILF3).
|
24719423 |
2014 |
Hepatitis C
|
0.030 |
Biomarker
|
disease |
BEFREE |
Moreover, poly(rC) binding protein 2 (PCBP2) interacts with NLRX1 to participate in the NLRX1-induced degradation of MAVS and the inhibition of antiviral responses during HCV infection.
|
28956771 |
2017 |
Frontotemporal dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Immunostaining for hnRNP E2 was performed on sections of frontal and temporal cortex with hippocampus from 80 patients with FTLD, stratified by pathology into FTLD-tau and FTLD-TDP type A, B and C subtypes, and by genetics into patients with C9orf72 expansions, MAPT or GRN mutations, or those with no known mutation, and on 10 healthy controls.
|
28666471 |
2017 |
Frontotemporal dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that another hnRNP family member, hnRNP E2, shows a striking accumulation within dystrophic neurites and cytoplasmic inclusions in the frontal cortex and hippocampus of a subset of FTLD-TDP cases belonging to pathological subtypes A and C, where hnRNP E2 was found to co-localize with 87% of TDP-43 immunopositive inclusions. hnRNP E2-positive inclusions were not seen in FTLD-TDP cases with the <i>C9orf72</i> expansion or in any other neurodegenerative disorders examined.
|
31213972 |
2019 |
Frontotemporal dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Using co-transfections, co-immunoprecipitations and RNAi we discovered that SRp75 binds to the proximal downstream intron of tau exon 10 at the FTDP-17 hotspot region; and that hnRNPG and hnRNPE2 interact with SRp75.
|
21723381 |
2011 |
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
PCBP2 may facilitate miR-151-5p and miR-16 promotion of glioma cell migration and invasion through mitigating the function of ARHGDIA.
|
26761212 |
2016 |
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Conversely, PCBP2 overexpression could increase the colony formation and invasion capability (P<0.01).
|
28787701 |
2017 |
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of PCBP2 could suppress proliferation, migration and invasion of glioma cells and promote apoptosis.
|
31693182 |
2020 |
Frontotemporal Lobar Degeneration
|
0.020 |
Biomarker
|
disease |
BEFREE |
Heterogeneous Nuclear Ribonucleoprotein E2 (hnRNP E2) Is a Component of TDP-43 Aggregates Specifically in the A and C Pathological Subtypes of Frontotemporal Lobar Degeneration.
|
31213972 |
2019 |
Frontotemporal Lobar Degeneration
|
0.020 |
Biomarker
|
disease |
BEFREE |
Present findings indicate an association between TDP-43 and hnRNP E2 which might underlie the pathogenetic mechanism of this form of FTLD.
|
28666471 |
2017 |
GRN-related frontotemporal dementia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Heterogeneous ribonuclear protein E2 (hnRNP E2) is associated with TDP-43-immunoreactive neurites in Semantic Dementia but not with other TDP-43 pathological subtypes of Frontotemporal Lobar Degeneration.
|
28666471 |
2017 |
GRN-related frontotemporal dementia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Heterogeneous Nuclear Ribonucleoprotein E2 (hnRNP E2) Is a Component of TDP-43 Aggregates Specifically in the A and C Pathological Subtypes of Frontotemporal Lobar Degeneration.
|
31213972 |
2019 |
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
KCNQ1OT1 serves as competing endogenous RNA (ceRNA) to up-regulate PCBP2 via sponging miR-145-5p in BC progression.
|
31827399 |
2019 |
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
KCNQ1OT1 serves as competing endogenous RNA (ceRNA) to up-regulate PCBP2 via sponging miR-145-5p in BC progression.
|
31827399 |
2019 |
Blast Phase
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report that loss of miR-328 occurs in blast crisis chronic myelogenous leukemia (CML-BC) in a BCR/ABL dose- and kinase-dependent manner through the MAPK-hnRNP E2 pathway.
|
20211135 |
2010 |
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The abnormal expression of PCBP2 was correlated with various carcinomas.
|
27461833 |
2016 |